Skip to main content

Dexcom Value Stock - Dividend - Research Selection

Dexcom

ISIN: US2521311074 , WKN: A0D9T1

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Insider Sell: EVP Chief Human Resources Officer Sadie Stern Sells Shares of DexCom Inc (DXCM)

2023-11-25
In the realm of insider trading, the actions of company executives can often provide valuable insights into the inner workings and future prospects of their organizations.

DexCom Inc. stock outperforms competitors on strong trading day

2023-11-24
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?

2023-11-23
Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.

EssilorLuxottica (ESLOY), Moncler Ink Luxury Eyewear Deal

2023-11-23
The first Moncler Lunettes collection produced with EssilorLuxottica (ESLOY) is called Fall-Winter 2024.

Here's Why You Should Retain Edward Lifesciences (EW) Stock Now

2023-11-23
Investors remain optimistic about Edward Lifesciences (EW) due to Surgical's differentiated portfolio and TMTT franchise.

DexCom's (NASDAQ:DXCM) 29% CAGR outpaced the company's earnings growth over the same five-year period

2023-11-22
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, you...

DXCM Crosses Above Key Moving Average Level

2023-11-22
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Enanta Pharmaceuticals (ENTA) and Arvinas Holding Company (ARVN)

2023-11-22
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

DexCom Inc. stock outperforms market on strong trading day

2023-11-22
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Dexcom Announces Upcoming Conference Presentation

2023-11-21
SAN DIEGO, November 21, 2023--DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29th.